← All Sponsors
SPONSOR

Kyverna Therapeutics

Total Trials
1
Recruiting
1
Phases
Phase 2, Phase 3
Conditions studied: Myasthenia GravisGeneralized Myasthenia Gravis
NCT06193889 Phase 2, Phase 3
Recruiting

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis
United States, Brazil, Germany View Trial →